Investors comparing iShares Biotechnology ETF and iShares U.S. Healthcare ETF must weigh biotechnology’s growth potential against the broader healthcare sector’s diversification and relative stability
New York, 12 October 2026 – The healthcare industry continues to attract investor attention as pharmaceutical...
New partnership with Mediplexus brings U.S. real-world healthcare data closer to Korean biopharma, medical technology, and AI companies
Minneapolis, Minnesota, 8 October 2026 – OneMedNet is expanding its presence in the Asia Pacific healthcare market after signing an agreement with...
New pilot projects aim to improve patient transfers, hospital coordination, and emergency readiness
Washington, DC, 5 October 2026 – When a serious injury occurs, getting the right care quickly can make a critical difference. But reaching the appropriate trauma center...
New FDA-cleared panel completes the company’s U.S. QIAstat Dx bloodstream infection portfolio, helping laboratories identify bacteria and antibiotic resistance markers faster
Germantown, Maryland, 28 September 2026 – Bloodstream infections can become serious quickly, making timely testing important for healthcare teams....
Uterine fibroids are among the most common benign gynecologic conditions affecting women of reproductive age. Yet their impact extends well beyond the uterus. Heavy menstrual bleeding, pelvic pain and pressure, anemia, reproductive concerns, and effects on daily functioning and...
Unlike in the early 1990s, clinical trials are now a well-developed business, with dedicated teams, specialised suppliers and sophisticated technology. Professionalisation has improved participant protection and the reliability of results. Yet, having watched this field develop, I wonder whether...
I've spent more than 25 years in oncology clinical trial research, including my time as Department Administrator for Investigational Cancer Therapeutics at MD Anderson. Here's the truth: the CRO industry is under more pressure than at any other point...
Clinical trial feasibility has traditionally focused on a familiar set of questions: Which countries have the right investigators? Which sites have experience in the therapeutic area? How many eligible patients does a site believe it can recruit? How quickly...
